Copertina

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Julian Pohl, Nirbaanjot Walia, Lukas Hofmann, Lena Wolters, Martin Schulz, Matthias Reinhardt, Brigitta Globke, Frank Tacke, Thomas Berg, Cornelius Engelmann
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
di: Isabella Lurje, et al.
Pubblicazione: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
di: Yu Shi, et al.
Pubblicazione: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
di: David Tornai, et al.
Pubblicazione: (2026)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
di: Ming Liu, et al.
Pubblicazione: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
di: Adriana Palom, et al.
Pubblicazione: (2026)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
di: William Chai, et al.
Pubblicazione: (2025)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
di: Nina Kimer, et al.
Pubblicazione: (2024)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
di: Thanawin Pramotedham, et al.
Pubblicazione: (2026)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
di: Deliang Huang, et al.
Pubblicazione: (2026)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
di: Emily Stephenson, et al.
Pubblicazione: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
di: Jimmy Che‐To Lai, et al.
Pubblicazione: (2026)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
di: Shuai Xia, et al.
Pubblicazione: (2025)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
di: Mo‐Yao Tan, et al.
Pubblicazione: (2024)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
di: Mary Yue Wang, et al.
Pubblicazione: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
di: Mary Yue Wang, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
di: Eduardo Vilar‐Gomez, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
di: Mei Chin Lim, et al.
Pubblicazione: (2026)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
di: Andrew W. Nguyen, et al.
Pubblicazione: (2026)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
di: Stephanie Tsai, et al.
Pubblicazione: (2025)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Soroor Owrangi, et al.
Pubblicazione: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
di: Louise J. M. Alferink, et al.
Pubblicazione: (2024)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
di: Abdulrahman Ismaiel
Pubblicazione: (2026)

Frailty Is Associated With All‐Cause and Acute Hospitalisations During 18 Months Follow‐Up in Older Patients With Inflammatory Bowel Disease
di: Anne B. Fons, et al.
Pubblicazione: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
di: Supachaya Sriphoosanaphan, et al.
Pubblicazione: (2025)

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
di: Parambir S. Dulai, et al.
Pubblicazione: (2024)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
di: Scott Silvey, et al.
Pubblicazione: (2025)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Pubblicazione: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
di: Bingqiong Wang, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)